Creatine Kinase, MB and Relative Percent

Also known as: CKMB PCT

Clinical Use

Use

The Creatine Kinase, MB and Relative Percent test is primarily used in the diagnosis and management of myocardial infarction (MI) or acute coronary syndrome. Creatine kinase MB (CK-MB) is an enzyme found in the heart muscles, and its levels increase when there is damage to the heart. This test helps in determining the extent of heart muscle damage and is critical in assessing patients with symptoms of acute coronary syndrome or suspected heart attacks, alongside troponin testing.

Special Instructions

Not provided.

Limitations

CK-MB levels can be elevated in conditions other than myocardial infarction, such as muscle trauma or diseases affecting skeletal muscles. It is also important to note that elevated levels of CK-MB can be transient and may return to normal even if a cardiac event has occurred, necessitating timely sample collection and analysis. Analytical interference from hemolysis or grossly lipemic specimens can affect test results, and stability is limited at room temperature.

Test Details

FDA Approved

New York Approved

Methodology

Immunoassay (CLIA)

Biomarkers

3 components

Creatine Kinase Total • CLIACK-MB Relative Percent • CLIACreatine Kinase, Isoenzyme MB • CLIA

LOINC Codes

Result Codes

2157-6 - CK SerPl-cCnc
13969-1 - CK MB SerPl-mCnc
12189-7 - CK MB CFr SerPl Calc

Result Turnaround Time

1 day

Specimen

Serum

Volume

2 mL

Minimum Volume

0.5 mL

Container

Serum Separator Tube (SST)

Collection Instructions

Allow specimen to clot for 15-20 minutes at room temperature. Separate from cells ASAP or within 2 hours of collection. Transfer to an ARUP Standard Transport Tube.